Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b, Randomized, Double-Blind, Multi-center Study Comparing Cross-linked Polyelectrolyte (CLP) With Placebo in Heart Failure Subjects

Next Previous
X
Search
Trial Profile

A Phase 2b, Randomized, Double-Blind, Multi-center Study Comparing Cross-linked Polyelectrolyte (CLP) With Placebo in Heart Failure Subjects

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Talinexomer (Primary)
  • Indications Heart failure
  • Focus Therapeutic Use
  • Acronyms STEPWISE
  • Sponsors Sorbent Therapeutics

    • Most Recent Events

    • 15 May 2014 Status changed from recruiting to active, no longer recruiting as reported by a Sorbent Therapeutics media release.
    • 30 Aug 2013 Planned End Date changed from 1 Oct 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov.
    • 11 Apr 2013 Patient dosing has commenced, according to a Sorbent Therapeutics media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top